vs
CareDx, Inc.（CDNA）与GIBRALTAR INDUSTRIES, INC.（ROCK）财务数据对比。点击上方公司名可切换其他公司
GIBRALTAR INDUSTRIES, INC.的季度营收约是CareDx, Inc.的1.9倍（$225.0M vs $117.7M），CareDx, Inc.同比增速更快（39.0% vs 24.9%），GIBRALTAR INDUSTRIES, INC.自由现金流更多（$26.2M vs $514.0K），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs -12.3%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
直布罗陀工业公司是专业建筑、基础设施及可再生能源产品制造商与分销商，主营通风系统、屋面配件、太阳能安装支架、园林景观产品等，主要服务北美地区住宅、商业建筑及清洁能源市场，专注提供创新可持续的客户解决方案。
CDNA vs ROCK — 直观对比
营收规模更大
ROCK
是对方的1.9倍
$117.7M
营收增速更快
CDNA
高出14.0%
24.9%
自由现金流更多
ROCK
多$25.7M
$514.0K
两年增速更快
CDNA
近两年复合增速
-12.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $225.0M |
| 净利润 | $2.8M | — |
| 毛利率 | — | 25.3% |
| 营业利润率 | 1.0% | 7.9% |
| 净利率 | 2.4% | — |
| 营收同比 | 39.0% | 24.9% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNAROCK
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $225.0M | ||
| Q3 25 | $100.1M | $310.9M | ||
| Q2 25 | $86.7M | $309.5M | ||
| Q1 25 | $84.7M | $290.0M | ||
| Q4 24 | $86.6M | $180.1M | ||
| Q3 24 | $82.9M | $277.1M | ||
| Q2 24 | $92.3M | $273.6M |
净利润CDNAROCK
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | — | ||
| Q3 25 | $1.7M | $-89.1M | ||
| Q2 25 | $-8.6M | $26.0M | ||
| Q1 25 | $-10.4M | $21.1M | ||
| Q4 24 | $87.7M | — | ||
| Q3 24 | $-10.6M | $34.0M | ||
| Q2 24 | $-4.6M | $32.2M |
毛利率CDNAROCK
| Q1 26 | — | — | ||
| Q4 25 | — | 25.3% | ||
| Q3 25 | — | 26.6% | ||
| Q2 25 | — | 28.4% | ||
| Q1 25 | — | 26.8% | ||
| Q4 24 | — | 29.0% | ||
| Q3 24 | — | 29.4% | ||
| Q2 24 | — | 30.5% |
营业利润率CDNAROCK
| Q1 26 | 1.0% | — | ||
| Q4 25 | -5.6% | 7.9% | ||
| Q3 25 | -0.2% | 12.8% | ||
| Q2 25 | -12.8% | 12.8% | ||
| Q1 25 | -15.8% | 8.8% | ||
| Q4 24 | 97.5% | 13.3% | ||
| Q3 24 | -16.6% | 15.6% | ||
| Q2 24 | -7.9% | 14.9% |
净利率CDNAROCK
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | — | ||
| Q3 25 | 1.7% | -28.6% | ||
| Q2 25 | -9.9% | 8.4% | ||
| Q1 25 | -12.2% | 7.3% | ||
| Q4 24 | 101.3% | — | ||
| Q3 24 | -12.8% | 12.3% | ||
| Q2 24 | -5.0% | 11.8% |
每股收益（稀释后）CDNAROCK
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.03 | $-2.98 | ||
| Q2 25 | $-0.16 | $0.87 | ||
| Q1 25 | $-0.19 | — | ||
| Q4 24 | $1.60 | — | ||
| Q3 24 | $-0.20 | $1.11 | ||
| Q2 24 | $-0.09 | $1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $115.7M |
| 总债务越低越好 | — | $0 |
| 股东权益账面价值 | — | $950.4M |
| 总资产 | $411.1M | $1.4B |
| 负债/权益比越低杠杆越低 | — | 0.00× |
8季度趋势，按日历期对齐
现金及短期投资CDNAROCK
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $115.7M | ||
| Q3 25 | $194.2M | $89.4M | ||
| Q2 25 | $186.3M | $43.3M | ||
| Q1 25 | $230.9M | $25.1M | ||
| Q4 24 | $260.7M | $269.5M | ||
| Q3 24 | $240.9M | $228.9M | ||
| Q2 24 | $228.9M | $179.1M |
总债务CDNAROCK
| Q1 26 | — | — | ||
| Q4 25 | — | $0 | ||
| Q3 25 | — | $0 | ||
| Q2 25 | — | $0 | ||
| Q1 25 | — | $0 | ||
| Q4 24 | — | $0 | ||
| Q3 24 | $0 | $0 | ||
| Q2 24 | $0 | $0 |
股东权益CDNAROCK
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $950.4M | ||
| Q3 25 | $311.1M | $951.8M | ||
| Q2 25 | $327.4M | $1.0B | ||
| Q1 25 | $379.3M | $1.0B | ||
| Q4 24 | $378.4M | $1.0B | ||
| Q3 24 | $273.2M | $1.0B | ||
| Q2 24 | $264.7M | $975.7M |
总资产CDNAROCK
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $1.4B | ||
| Q3 25 | $432.3M | $1.4B | ||
| Q2 25 | $444.3M | $1.5B | ||
| Q1 25 | $489.6M | $1.4B | ||
| Q4 24 | $491.1M | $1.4B | ||
| Q3 24 | $477.0M | $1.4B | ||
| Q2 24 | $466.8M | $1.4B |
负债/权益比CDNAROCK
| Q1 26 | — | — | ||
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.00× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | 0.00× | 0.00× | ||
| Q2 24 | 0.00× | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $35.5M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $26.2M |
| 自由现金流率自由现金流/营收 | 0.4% | 11.7% |
| 资本支出强度资本支出/营收 | — | 4.1% |
| 现金转化率经营现金流/净利润 | 1.54× | — |
| 过去12个月自由现金流最近4个季度 | — | $120.6M |
8季度趋势，按日历期对齐
经营现金流CDNAROCK
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $35.5M | ||
| Q3 25 | $37.4M | $73.0M | ||
| Q2 25 | $9.9M | $44.9M | ||
| Q1 25 | $-26.6M | $13.7M | ||
| Q4 24 | $21.9M | $19.9M | ||
| Q3 24 | $12.5M | $64.7M | ||
| Q2 24 | $18.9M | $36.5M |
自由现金流CDNAROCK
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $26.2M | ||
| Q3 25 | — | $64.8M | ||
| Q2 25 | — | $27.3M | ||
| Q1 25 | — | $2.3M | ||
| Q4 24 | — | $14.1M | ||
| Q3 24 | — | $60.5M | ||
| Q2 24 | — | $33.5M |
自由现金流率CDNAROCK
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | 11.7% | ||
| Q3 25 | — | 20.8% | ||
| Q2 25 | — | 8.8% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | — | 21.8% | ||
| Q2 24 | — | 12.2% |
资本支出强度CDNAROCK
| Q1 26 | — | — | ||
| Q4 25 | — | 4.1% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 5.7% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 1.1% |
现金转化率CDNAROCK
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 22.30× | — | ||
| Q2 25 | — | 1.73× | ||
| Q1 25 | — | 0.65× | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Financial Results Total | $85.0M | 72% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
| Other | $6.4M | 5% |
ROCK
| Transferred At Point In Time | $183.5M | 82% |
| Infrastructure | $22.5M | 10% |
| Other | $18.9M | 8% |
